Actively Recruiting
Study of Stopping or Continuing Somatostatin Analogues After PRRT in Mid, Hind-Gut, and Pancreatic Neuroendocrine Tumours
Led by Australasian Gastro-Intestinal Trials Group · Updated on 2026-09-10
78
Participants Needed
17
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Neuroendocrine tumours NETs are slow-growing cancers often found in the gut that can spread to organs like the liver, bones, and lymph nodes. Many NETs do not produce excess hormones, and their main treatment is somatostatin analogues SSA, which slow tumour growth and reduce hormone production. Over time, most patients experience tumour growth despite SSA therapy. This study investigates whether continuing SSA treatment after starting Peptide Receptor Radionuclide Therapy PRRT, a targeted radiotherapy, benefits patients with grade 1 and 2 well-differentiated mid, hind-gut, or pancreatic NETs that have progressed on SSA therapy. Participants will be randomly assigned to one of two groups those who continue SSA injections during and after PRRT, and those who stop SSA after receiving their last injection before starting PRRT. PRRT is given as the next treatment step for patients with inoperable metastatic NETs who have shown progression despite SSA therapy. The study aims to estimate the 20-month progression-free survival rate for both groups and assess feasibility factors like recruitment and patient acceptance of stopping SSA. During the study, patients will receive PRRT and either continue or cease SSA injections according to their group assignment. Researchers will monitor tumour progression, quality of life, cost-effectiveness, psychological impacts, overall survival, and the timing of any further treatments over 20 months. Study assessments include imaging scans, performance status evaluations, and collection of clinical data. This trial is open-label and will help clarify the role of continuing SSA therapy alongside PRRT in this patient population.
CONDITIONS
Brief Title
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
Research Team
J
Julia Kuszewski
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here